Evidence map›Paper›PMID 26885609›Full record

ArticleOncotarget2016

SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells.

Giulia Pinton, Sara Zonca, Arcangela G Manente, Maria Cavaletto, Ester Borroni, Antonio Daga, Puthen V Jithesh, Dean Fennell, Stefan Nilsson, Laura Moro

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Molecular mechanisms of estrogen receptorThe Journal of international medical research · 2019
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Giulia PintonDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.
Sara ZoncaDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.
Arcangela G ManenteDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.
Maria CavalettoDepartment of Sciences and Technological Innovation, University of Piemonte Orientale "A. Avogadro", 15121 Alessandria, Italy.
Ester BorroniDepartment of Health Sciences, University of Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.
Antonio DagaDepartment of Integrated Oncological Therapies, IRCCS San Martino-IST, 16132 Genova, Italy.
Puthen V JitheshDivision of Biomedical Informatics Research, Sidra Medical and Research Center, 26999 Doha, Qatar.
Dean FennellDepartment of Cancer Studies, Cancer Research UK Leicester Centre, University of Leicester, LE1 7RH Leicester, UK.
Stefan NilssonDepartment of Biosciences and Nutrition, Karolinska Institutet, S-141 57 Huddinge, Sweden.
Laura MoroDepartment of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITCancer Research UK · GBIstituti di Ricovero e Cura a Carattere Scientifico · ITKaro Pharma (Sweden) · SESidra Medical and Research Center · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this report, we show that malignant pleural mesothelioma (MPM) patients whose tumors express high levels of AKT1 exhibit a significantly worse prognosis, whereas no significant correlation with AKT3 expression is observed. We provide data that establish a phosphorylation independent role of AKT1 in affecting MPM cell shape and anchorage independent cell growth in vitro and highlight the AKT1 isoform-specific nature of these effects.We describe that AKT1 activity is inhibited by the loss of SIRT1-mediated deacetylation and identify, by mass spectrometry, 11 unique proteins that interact with acetylated AKT1.Our data demonstrate a role of the AKT1/SIRT1/FOXM1 axis in the expression of the tumor suppressor ERβ. We further demonstrate an inhibitory feedback loop by ERβ, activated by the selective agonist KB9520, on this axis both in vitro and in vivo.Our data broaden the current knowledge of ERβ and AKT isoform-specific functions that could be valuable in the design of novel and effective therapeutic strategies for MPM.

Indexed as

AnimalsApoptosisBiomarkers, TumorCell ProliferationEstrogen Receptor betaEstrogensForkhead Box Protein M1HumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiceMice, NudePleural NeoplasmsProto-Oncogene Proteins c-aktAKT1 protein, humanBiomarkers, TumorEstrogen Receptor betaEstrogensForkhead Box Protein M1FOXM1 protein, humanProto-Oncogene Proteins c-aktSIRT1 protein, humanSirtuin 1AKT1estrogen receptor betamalignant pleural mesotheliomaSIRT1

Identifiers

PMID26885609
PMCPMC4924721
OpenAlexW2306075661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.